【摘要】 共征集374例早孕妇女于负压吸宫术前随机口服米非司酮25mg q12h×4(组Ⅰ,n=124)、米索前列醇800μm(组Ⅱ,n=126)或不用任何药物(组Ⅲ,n=124)。结果显示组Ⅰ～Ⅲ Hegar氏扩张器无阻力通过宫颈内口的最大直径分别为6.6±0.8,7.0±00.9和4.1±1.4mm((?)±S,下同);术中出血量分别为15.4±12.0,11.4±9.6和23.1±18.5ml;术中副反应发生率分别为32.26,27.78％和54.03％。三组间均有极显著差异(P<0.0001),且米索扩张宫颈和减少术中出血的临床效果比米非司酮更明显。更多还原

【Abstract】 This study enrolled 374 early pregnant women requiring vacuum aspiration. They were orally administered in random with mifepristone 25mg × 4 (Group Ⅰ ) , miso prostol 800μg (Group Ⅱ )or no medication (Group Ⅲ ) prior to operation. The results showed that in Group Ⅰ to Ⅲ , maximum diameters of Hegar ’ s dilator passing through the cervix resistlessly were 6. 6 ± 0. 8, 7. 0 ± 0. 9 and 4. 1 ± 1. 4mm (mean ± SD, so were the following values) respectively, while volumes of blood loss in operation were 15. 4±12. 2,11. 4±9. 6 and 23. 1 ± 18. 5 ml respectively, and incidences of side effects in operation 32. 26%, 27. 78% and 64. 03% respectively. There were significant differences in these parameters between the three groups(P<0. 0001). In addition, misoprostol presented more marked effects on cervical dilatation and decrease in blood loss in operation.更多还原